292 related articles for article (PubMed ID: 31336250)
1. Optimal combination of beneficial mutations for improved ADCC effector function of aglycosylated antibodies.
Yoon HW; Jo M; Ko S; Kwon HS; Lim CS; Ko BJ; Lee JC; Jung ST
Mol Immunol; 2019 Oct; 114():62-71. PubMed ID: 31336250
[TBL] [Abstract][Full Text] [Related]
2. Engineered aglycosylated full-length IgG Fc variants exhibiting improved FcγRIIIa binding and tumor cell clearance.
Jo M; Kwon HS; Lee KH; Lee JC; Jung ST
MAbs; 2018; 10(2):278-289. PubMed ID: 29173039
[TBL] [Abstract][Full Text] [Related]
3. An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIa
Kang TH; Lee CH; Delidakis G; Jung J; Richard-Le Goff O; Lee J; Kim JE; Charab W; Bruhns P; Georgiou G
Front Immunol; 2019; 10():562. PubMed ID: 30984171
[TBL] [Abstract][Full Text] [Related]
4. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
[TBL] [Abstract][Full Text] [Related]
5. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs.
Mimoto F; Kadono S; Katada H; Igawa T; Kamikawa T; Hattori K
Mol Immunol; 2014 Mar; 58(1):132-8. PubMed ID: 24334029
[TBL] [Abstract][Full Text] [Related]
6. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
7. Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells.
Jung ST; Reddy ST; Kang TH; Borrok MJ; Sandlie I; Tucker PW; Georgiou G
Proc Natl Acad Sci U S A; 2010 Jan; 107(2):604-9. PubMed ID: 20080725
[TBL] [Abstract][Full Text] [Related]
8. Structural consequences of aglycosylated IgG Fc variants evolved for FcγRI binding.
Ju MS; Na JH; Yu YG; Kim JY; Jeong C; Jung ST
Mol Immunol; 2015 Oct; 67(2 Pt B):350-6. PubMed ID: 26153451
[TBL] [Abstract][Full Text] [Related]
9. Engineering Aglycosylated IgG Variants with Wild-Type or Improved Binding Affinity to Human Fc Gamma RIIA and Fc Gamma RIIIAs.
Chen TF; Sazinsky SL; Houde D; DiLillo DJ; Bird J; Li KK; Cheng GT; Qiu H; Engen JR; Ravetch JV; Wittrup KD
J Mol Biol; 2017 Aug; 429(16):2528-2541. PubMed ID: 28694069
[TBL] [Abstract][Full Text] [Related]
10. The "less-is-more" in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity.
Pereira NA; Chan KF; Lin PC; Song Z
MAbs; 2018 Jul; 10(5):693-711. PubMed ID: 29733746
[TBL] [Abstract][Full Text] [Related]
11. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
[TBL] [Abstract][Full Text] [Related]
12. Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies.
Liu Z; Gunasekaran K; Wang W; Razinkov V; Sekirov L; Leng E; Sweet H; Foltz I; Howard M; Rousseau AM; Kozlosky C; Fanslow W; Yan W
J Biol Chem; 2014 Feb; 289(6):3571-90. PubMed ID: 24311787
[TBL] [Abstract][Full Text] [Related]
13. A variant human IgG1-Fc mediates improved ADCC.
Stewart R; Thom G; Levens M; Güler-Gane G; Holgate R; Rudd PM; Webster C; Jermutus L; Lund J
Protein Eng Des Sel; 2011 Sep; 24(9):671-8. PubMed ID: 21596686
[TBL] [Abstract][Full Text] [Related]
14. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
[TBL] [Abstract][Full Text] [Related]
15. Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.
Zhang D; Goldberg MV; Chiu ML
J Biol Chem; 2016 Dec; 291(53):27134-27146. PubMed ID: 27856634
[TBL] [Abstract][Full Text] [Related]
16. Isolation and characterization of IgG1 with asymmetrical Fc glycosylation.
Ha S; Ou Y; Vlasak J; Li Y; Wang S; Vo K; Du Y; Mach A; Fang Y; Zhang N
Glycobiology; 2011 Aug; 21(8):1087-96. PubMed ID: 21470983
[TBL] [Abstract][Full Text] [Related]
17. Engineering IgG1 Fc Domains That Activate the Complement System.
Lee CH; Delidakis G
Methods Mol Biol; 2022; 2421():187-200. PubMed ID: 34870820
[TBL] [Abstract][Full Text] [Related]
18. Full-length recombinant antibodies from
Rashid MH
MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
[TBL] [Abstract][Full Text] [Related]
19. Modulating IgG effector function by Fc glycan engineering.
Li T; DiLillo DJ; Bournazos S; Giddens JP; Ravetch JV; Wang LX
Proc Natl Acad Sci U S A; 2017 Mar; 114(13):3485-3490. PubMed ID: 28289219
[TBL] [Abstract][Full Text] [Related]
20. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions.
Schlothauer T; Herter S; Koller CF; Grau-Richards S; Steinhart V; Spick C; Kubbies M; Klein C; Umaña P; Mössner E
Protein Eng Des Sel; 2016 Oct; 29(10):457-466. PubMed ID: 27578889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]